GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.
about
Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications StudyTreatment of adult growth hormone deficiency: who, why and how? A reviewHypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study.Suprasellar germ cell tumours: specific problems and the evolution of optimal management with a combined chemoradiotherapy regimen.Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency.Should we start and continue growth hormone (GH) replacement therapy in adults with GH deficiency?Pediatric brain tumor treatment: growth consequences and their managementSheehan's syndrome: Newer advancesAdult growth hormone deficiency.Justified and unjustified use of growth hormone.Use of growth hormone for prevention or treatment of effects of aging.Adult growth hormone deficiency: current concepts.Advances in growth hormone therapy: a new registry tool.Long-term challenges in growth hormone treatment.Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapyGender-, age- and time-dependent dosing of growth hormone in adults - real-world data from a decade of clinical practice in Germany.Sheehan's syndrome presenting as psychosis: a rare clinical presentation.Idiopathic adult growth hormone deficiency.Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients.Hypopituitarism oddities: craniopharyngiomas.Deep vein thrombosis in a patient of Sheehan's syndrome: Autoimmunity or hypercoagulabilty.Growth hormone replacement therapy in adults with growth hormone deficiency: benefits and cost-effectiveness.Myths and truths of growth hormone and testosterone therapy in heart failure.Diagnosis and treatment of growth hormone deficiency in adults.Possible synergism of physical exercise and ghrelin-agonists in patients with cachexia associated with chronic heart failure.Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity.Sheehan's syndrome: new insights into an old disease.Is hepatic steatosis associated with left ventricular mass index increase in the general population?Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician.Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors.Elderly people with hypothalamic-pituitary disease and growth hormone deficiency: lipid profiles, body composition and quality of life compared with control subjects.Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database.Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study.Do all adults with growth hormone deficiency require growth hormone treatment?Etiology of hypopituitarism in tertiary care institutions in Turkish population: analysis of 773 patients from Pituitary Study Group database.Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.Sex Differences in Muscle Wasting.Basal growth hormone concentration increased following a weight loss focused dietary intervention in older overweight and obese women.Long-term safety of growth hormone-A combined registry analysis.
P2860
Q24595013-E72207D1-D071-4242-829E-BFCC0257DAB7Q28278957-64143D50-4B27-44FC-9567-AE4268B025BEQ30632833-97B37D4F-DE44-45DC-85E8-DA88C3CEB1D0Q30734734-9D589661-C46E-4BA7-8306-EDDA429DDACBQ31000138-2C0BE252-A51B-4BD6-8A40-4603C61D1E06Q34087419-B1456AD9-7A75-4BA2-83D9-B8B58C27BD14Q34106670-23DF17E9-4FD9-44A6-92C4-11F47623D21BQ35244596-2FCAFE35-02CA-4A39-9A84-C0F3B315DA86Q35244635-2AE5EA7B-1C9D-43FB-B520-88EC0108020AQ35520520-0CD60F20-66D7-462C-8581-D2ACEDF2C581Q35860335-A1CB9A11-0790-4F9B-BD04-E078ACE734C0Q35943964-4DAB63EC-795B-4B31-B28C-93CFF1E773B1Q35980569-CA3DED21-F788-4561-8022-E592F7DCF536Q35980586-C81DCF65-7CB9-46BB-9785-12D755FFB8C2Q36088749-AF7AF80E-1359-49DC-845C-D4BEFBB13819Q36301950-A62AF1E7-4660-488D-B126-F060254A0D7BQ36670104-A34E2E7D-999A-4A77-86AA-B658DA17C391Q36885877-87C3EF61-57B7-482F-96ED-24A23B6BE4D3Q36915085-C4AF7566-2298-4953-902C-B1241D11C736Q37050098-30E1E2AF-09D6-40F0-9A60-FF75FF35B55CQ37314506-758032BE-3CDA-4D02-876F-C2019E841F61Q37763178-C2EC0D0F-1B47-47FE-9F4A-E23D403DE8A3Q37895679-558F230B-4584-4558-AB41-AC435D56A971Q38102923-D95A9E95-4F08-417A-B916-3A05B999746AQ38172031-2390E7D8-CA6F-4CC2-A580-0353E0E0A77EQ38205919-98E3EE12-11C9-40B1-B5F4-C1407EFFE96DQ38577314-3B44B659-6A30-4577-8C22-EFE1C1A7750EQ38663332-F1777268-8C65-42A0-8F06-DFE6DA939192Q38687230-6297D552-3AAB-4AF9-8525-88F90F0BA332Q40415626-77015C23-7662-421D-87C7-EFF4737854C5Q40735729-33972499-78A5-42E3-BC65-636C9F23FF3FQ42632946-CDD941D2-5F78-4FD5-AF63-FC062F3AB148Q42634901-14DBB90E-827C-44D9-BB2D-5FA9F9116D6DQ43586022-C247CCC5-C0F1-404F-9DBF-0EFA532FCBC4Q44627503-12A55A1A-E675-433E-B1A1-3D0F8A78CF44Q46352393-E2FBE6BF-BC38-4828-A231-7CDC9559DDFEQ46887493-68A289E8-65CB-4336-8278-C387EC6D2677Q47311543-A42F272C-396D-4704-9E03-92A4A6A23343Q47327006-307FEA9F-74CC-4284-AD99-BBA6ED33C881Q47750239-B7B44235-EF88-4440-A2FA-031EB6E43F61
P2860
GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
GH replacement in 1034 growth ...... cteristics, dosing and safety.
@ast
GH replacement in 1034 growth ...... cteristics, dosing and safety.
@en
type
label
GH replacement in 1034 growth ...... cteristics, dosing and safety.
@ast
GH replacement in 1034 growth ...... cteristics, dosing and safety.
@en
prefLabel
GH replacement in 1034 growth ...... cteristics, dosing and safety.
@ast
GH replacement in 1034 growth ...... cteristics, dosing and safety.
@en
P2093
P2860
P1476
GH replacement in 1034 growth ...... cteristics, dosing and safety.
@en
P2093
Bengtsson BA
Hernberg-Stâhl E
P2860
P304
P356
10.1046/J.1365-2265.1999.00695.X
P577
1999-06-01T00:00:00Z